WEBULL
WebtradeDownload

Is Agios Pharmaceuticals (AGIO) Undervalued On Its PYRUKYND Expansion Story?

Simply Wall St · 1d ago

Agios Pharmaceuticals (AGIO) has drawn fresh attention after recent share price moves that contrast with mixed return figures over the past year. Investors are weighing this performance against the biopharmaceutical group’s rare disease focus.

Recent trading has been choppy for Agios Pharmaceuticals, with a 1-day share price return that declined 2.23%, even though the 7-day and 30-day share price returns of 3.76% and 4.75% suggest short-term momentum is still intact. That near term strength contrasts with a 90-day share price return that fell 5.55% and a 1-year total shareholder return that slipped 8.39%, while the 3-year total shareholder return of 39.35% points to a more constructive longer history than the 5-year total shareholder return, which declined 26.01%.

Scan beyond Agios Pharmaceuticals and compare this rare disease player with other hand picked biopharma opportunities using the 38 healthcare AI stocks.

Agios Pharmaceuticals has a focused rare disease pipeline and a share price that has moved around sharply in recent months. The key issue now is whether that story is already fully reflected in the current valuation.

Most Popular Narrative: 22% Undervalued

Agios Pharmaceuticals closed at $34.19 compared with a widely followed fair value assumption of $44.00, which presents the stock as materially discounted before even considering what would need to happen for that gap to close.

Upcoming potential FDA approval and commercial launch of PYRUKYND for thalassemia in the U.S. is described as likely to expand Agios' addressable market, supported by the high rate of disease diagnosis through newborn screening and well-defined patient populations.

See why 7 investors see Agios Pharmaceuticals as 22% undervalued.

Result: Fair Value of $44 (UNDERVALUED)

Still, the Agios Pharmaceuticals story leans heavily on PYRUKYND across multiple indications, and any safety or uptake issues could quickly challenge that undervaluation case.

Find out about the key risks to this Agios Pharmaceuticals narrative.

Another View On Agios Pharmaceuticals' Valuation

On the other side of the ledger, Agios Pharmaceuticals looks expensive on a simple P/S check. The stock trades around 20.8x sales versus 12.9x for the US Biotechs industry and 5.4x for peers, while the fair ratio model points to just 0.1x. This flags meaningful valuation risk if sentiment cools.

That gap between the fair ratio and today’s P/S level is wide enough that it puts the whole undervaluation story in question for anyone who cares about what they are paying per dollar of current revenue. See what the numbers say about this price — find out in our valuation breakdown.

NasdaqGS:AGIO P/S Ratio as at Sep 2026
NasdaqGS:AGIO P/S Ratio as at Sep 2026

Next Steps

Mixed signals around Agios Pharmaceuticals can be confusing, so consider reviewing the data yourself promptly and deciding where you land on the story. To see both sides laid out in one place, start with 2 key rewards and 1 important warning sign

Looking for more ideas beyond Agios Pharmaceuticals?

If the Agios Pharmaceuticals story leaves you unsure, cast the net wider with other potential opportunities that fit different risk levels, income needs, and balance sheet profiles using the Simply Wall Street Screener.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.